No Picture
News

Brickell Biotech Doses First Subject in Phase 1 Study of DYRK1A Inhibitor BBI-02

Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, […]

No Picture
News

Historic $200 Million Commitment to the University of Colorado Anschutz Medical Campus Fuels Advancements in Treatments and Cures

The University of Colorado Anschutz Medical Campus today announced the creation of the Gates Institute, a state-of-the-art facility that will focus on rapidly translating laboratory findings into regenerative, cellular and gene therapies for patients. Click […]